A 48-week real-world effectiveness of nemolizumab for pediatric patients with atopic dermatitis
Published: 30 July 2026| Version 1 | DOI: 10.17632/j2twrwcd2h.1
Contributors:
Teppei Hagino, Yohei Takahashi, , Eita Fujimoto, Naoko KandaDescription
Supplementary Figure 1. Transition of total eczema area and severity index (EASI), regional EASI (head and neck, trunk, upper limbs, and lower limbs), and peak pruritus–numerical rating scale (PP-NRS) scores in pediatric patients with atopic dermatitis treated with nemolizumab (n = 23). Data are shown as mean ± standard deviation at weeks 0, 4, 8, 12, 16, 24, 36, and 48 of treatment. Analyses were based on observed cases, and the number of evaluable patients differed by time point; no imputation was performed. Supplementary Methods Supplementary Table 1. Clinical outcomes at weeks 4, 24, and 48 in dupilumab-naïve and dupilumab-experienced patients
Files
Categories
Medicine, Immunology, Pharmacology, Dermatology, Clinical Research, Atopic Dermatitis